I'm a native of Brazil by way of California for two decades. I am a value-obsessed full-time investor who focuses on hidden biotech and tech gems with long-term hold mentality for maximum returns. Go Golden Bears
Undergraduate in the School of Foreign Service at Georgetown University. Majoring in International Political Economics and International Business Diplomacy. Interested in macro trends and contrarian investing.
Anita Dushyanth is a Biotechnology Technology and Medical Devices Analyst with Zacks Investment Research.
She has worked as a researcher in the field of Bioengineering at the University of California, Los Angeles (UCLA) for over 10 years. Her expertise includes research that delves into the biomechanics of the human body, degenerative disease progression, quantitative image analysis and optimization, and design and development of medical compliant devices. She has published and presented several research articles and has also been a peer reviewer and an editor for a number of prestigious journals in the field of biomedical engineering. Prior to that, Anita worked as a researcher at the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF).
Anita holds a PhD degree in Bioengineering from UCLA, M.S. in Biomedical Engineering from Wright State University, Dayton, OH and B.S. in Instrumentation Engineering from the University of Madras, India.
I am individual investor with over 35 years investing experience. I have traded almost everything you can over that time. I prefer investing in microcaps as there can be above average rewards along with higher risk. The areas I follow very closely are: Technology, Intellectual Property, Precious Metals, Rare Earths, mining companies and Biotechs. Picking the emerging leaders can provide huge rewards for early investors. I blog on topics that are of interest to me and on ones that I hope will generate good discussion. I don’t consider myself an expert in any one area, but know a little about a lot of things. I believe as soon as we stop learning, we stop living.
I am also a guest contributor to the Patent Stock Review, the most comprehensive investment research and news aggregation service on Wall Street, covering publicly traded companies seeking to monetize their IP portfolios, or "Patent Play Stocks."
That's what I would like to bring across more than anything. I am not a professional trader/investor. I am not even remotely wealthy. I can not make you rich. I have made some money in short term trading and I have lost some money doing the same. Short term trading has been a wash for me as any profits taken were quickly usurped by idiotic losses.
Why? Because I rushed in to trading in companies that I knew next to nothing about. Maybe I saw a newsletter. Maybe a friend mentioned something. However it happened, in retrospect, it was the wrong reason to invest. It sure felt good when a trade was a winner, but I'd take those profits and either try and chase, or would invest in a stinker immediately afterwards.
Through it all though, I have maintained several stocks that I was long out of the gate on, because I saw potential when I studied the companies. These were companies that I saw as having massive upside with minimal risk. Consequently, I invested more in these longs than I ever risked on the short term plays.
These are the stocks that I would like to write about, as I feel they are worth my time to write about.
Everything I write is, of course, my opinion, and in no way should be taken as investment advice.
I am going to write and I don't care if you read it.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
I'm an investor focused on IP situations, and have invested in the market for countless years. Past employment has been in the investment banking, venture capital, and hedge fund spaces. I currently work in corporate development and invest my excess capital in my spare time.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Consultant / Investment research writer, focusing on natural resource companies & select other small cap opportunities. MBA, Financial Analysis, Top 12 rated business school, New York University (NYU) Stern School of Business.
Designated a Chartered Financial Analyst, "CFA" He's published hundreds of investment articles & CEO interviews on a number of prominent [Metals & Mining] and [Investment] websites including:
EpsteinResearch, InvestorIdeas, InvestingNews, MiningFeeds, Equity.Guru, Investing.com, Equities.com, CNAFinance, CountingPips, StockHouse, SeekingAlpha, TalkMarkets, CEO.CA, Investor-SMS.de, SmallCapMarkets.
On Twitter: @peterepstein2 Email: firstname.lastname@example.org
Hi everyone, my name is Khen Elazar and I am a 25 years old student for political science. I currently work in an insurance agency in Israel, and studying to become a financial adviser. Hopefully, I will find the time to study for a master's degree in the near future.
I am investing in the stock market since I was 17 years old. I did it with the help and guidance of my father who is an investment adviser. I used to invest in value and growth stocks, and in Israeli junk bonds. Over the past two years, I have been investing mainly in dividend growth stocks.
I also enjoy reading and study new things. I am a political junkie and sport enthusiast, mainly soccer and NBA.
Developer, Chief Strategist and Head Writer of AllanTrends.com, a trading service based upon a proprietary algorithm that identifies the dominant trend of any stock, index or ETF.
I am an analyst and Level II Candidate in the CFA Program that has gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Accounting Professor teaching financial accounting; PhD, CPA, CMA, CGMA. He holds a BSBA from the University of Arizona, a Macc. from the University of Arizona, and his PhD from Virginia
Tech. He worked in public accounting, industry, as a CFO, a government auditor for the California Auditor General and in litigation support. His publications have been used and filed in Court proceedings by the Securities and Exchange Commission, he has been quoted in the Wall Street Journal, and his background includes litigation support and expert testimony in cases involving business litigation (e.g., Ford, GM, and so on) in CA, AZ, TX, NV and MN. He enjoys trading stocks and securities, teaching his classes, and publishing in related areas. Also home repair and remodel, snorkling, and cruises to the Carribean.
I have an MA in Economics from The George Washington University and an MBA in Finance from Columbia and a CFA.
I work for a financial services company in the product development and credit areas, with over 30 years experience. All trading by myself and family members is pre-approved to ensure no conflict of interest.
I consider myself a long-term buy & hold investor with a focus on US equities. My preference is for reasonably valued companies that are leaders in their field (preferably with a defensible moat) that generate significant cash flow long-term. I also attempt to take advantage of what I consider market overreaction and herd mentality to the companies that I follow.
(Note: updates to my SA articles & some original articles may appear in my blog. So check it (below) from time to time.)
I am a retired broker from TD Ameritrade (series 7,63,24 & 4)as of January 1st (2010). However, I have worked in general management in manufacturing and business logistics as well as railroading for a number of Fortune 500 companies. My earliest post college experiences included 2 years in the US Army (Staff Sergeant) in the 1st Infantry Division in South Vietnam. My degree is in Economics from the University of Maryland and I hold an MBA as well. My current activities, besides day trading include projects associated with the Texas Master Naturalist and the Texas Bluebird Society - 2013 Texas Bluebirder of The Year, getting back into shape (recently hit my goal after losing 35 lbs), jogging, swimming, resistance training and following the exploits of my children and grandchildren.
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments.
My level of trading escalated after graduating from college, primarily as a result of my relationship with the founder of the Silicon Valley venture capital firm, Institutional Venture Partners, (Netflix, Twitter, Oracle). By focusing on VC backed companies, I soon learned the advantage of investing in promising companies before they became household names. My interest in startups has never waned, and has become my primary focus today.
Seeking alpha has been one of the "go-to" sites for the investors in our family. We would like to strike a perfect balance between short term trading and long term investing, hence the name "Tradevestor".Good luck investing. In the interest of full disclosure, this is a group account handled by Father and Son. The Father was a trader for quite a few years years with mixed returns, while the son started out a few years ago with DGI and has slowly convinced the Patriarch towards investing rather than trading.
Disclaimer: Please do your own due diligence before buying or selling any stock. Ideas and thoughts presented in the articles are not professional recommendations.
My investing activities began with index funds when I was about thirteen. At the age of eighteen, I began investing in individual companies. Since I was always interested in science and technology, I started my focus in tech and biologically focused companies. Currently, I have over three years of experience with investing in individual stocks (primarily in biotech, med-tech, and pharmaceuticals). I focus primarily on small to mid cap companies that exhibit strong revenue growth and/or innovative clinical developments. I am currently an undergraduate student pursuing a degree in Molecular Biology & Biochemistry, with aspirations of getting an MBA in Finance.
I added stock and bond analysis to my IT consulting business at the request of a small cap investment specialist in 2002. For my own account I invest mainly in technology and biotechnology stocks, but occasionally I invest in industrial, retail and other stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.